Home / Letter From The Editor / June 8, 2019

June 8, 2019

Jun 8, 2019

Most times when the FDA calls for an early discontinuation of a drug study, it is because there are complications, or the drug does not work at all. It is not often that good results cause an early discontinuation. This week our new intern, Marian Ayad, BPharm, PharmD candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, has a special report on a drug that worked so well that the FDA called the study off early, and the ADA actually changed their guidelines because of the results. Click here to find out what drug and what the ADA changed.



We can make a difference!


Dave Joffe